Oleg Chebotarev, MD
Cardiovascular Disease · Appleton, WINPI 1780647552
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,875 of the $22,263 with a category attached, or 71.3%. 30 manufacturers reported payments, led by AstraZeneca at 54.7% of the total. Among cardiovascular disease clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 343 payments — averaging $64.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$12K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$7K
- Johnson & Johnson$1K
- Boston Scientific$634
- Pfizer$343
- E.r. Squibb & Sons, L.L.C.$189
- plus $1K from 24 others
What the payments were for
- Speaking & faculty fees$15,87571%
- Travel & lodging$1,1445%
- Food & beverage$5,22323%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 27 | $12,167 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 31 | $6,585 |
| Johnson & Johnson | 117 | $1,031 |
| Boston Scientific | 27 | $634 |
| Pfizer | 27 | $343 |
| E.r. Squibb & Sons, L.L.C. | 13 | $189 |
| Amarin Pharma, Inc. | 11 | $157 |
| Sanofi | 3 | $150 |
| Gilead | 29 | $139 |
| Boehringer Ingelheim | 8 | $124 |
| Novartis | 8 | $101 |
| Amgen | 7 | $94 |
| Merck | 6 | $85 |
| Lexicon Pharmaceuticals, Inc. | 3 | $58 |
| Sanofi-aventis U.S. LLC | 4 | $45 |
| Bridgebio Pharma, Inc. | 2 | $44 |
| Bayer | 3 | $39 |
| Actelion Pharmaceuticals US, Inc. | 2 | $30 |
| Regeneron Healthcare Solutions, Inc. | 2 | $29 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Abbott | 2 | $27 |
| Bracco Diagnostics Inc. | 1 | $24 |
| Biomerieux Inc | 1 | $23 |
| Cook Medical LLC | 2 | $23 |
| Terumo Medical Corporation | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Vifor Pharma, Inc. | 1 | $15 |
| Scpharmaceuticals Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$5,825
- LOKELMA$5,796
- LifeVest$5,769
- WATCHMAN FLX$143
- MULTAQ$125
How this compares
$22,263 in reported general payments places this provider in the 90th percentile of 322 cardiovascular disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 474 | $395,302 |
| EliquisApixaban | 420 | $360,301 |
| EntrestoSacubitril/Valsartan | 416 | $346,536 |
| FarxigaDapagliflozin Propanediol | 224 | $178,160 |
| XareltoRivaroxaban | 101 | $78,871 |
| OzempicSemaglutide | 49 | $64,308 |
| Repatha SureclickEvolocumab | 47 | $42,918 |
| BrilintaTicagrelor | 34 | $22,310 |
| Metoprolol Succinate | 852 | $9,873 |
| Spironolactone | 1,187 | $7,031 |
| Amiodarone Hcl | 302 | $5,233 |
| Furosemide | 1,003 | $4,747 |
| Losartan Potassium | 505 | $4,368 |
| Potassium Chloride | 196 | $4,183 |
| Bumetanide | 131 | $3,702 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $124 | $395,302474 claims |
| PfizerEliquis | $343 | $360,301420 claims |
| NovartisEntresto | $101 | $346,536416 claims |
| AstraZenecaFarxiga, Brilinta | $12,167 | $200,470258 claims |
| Johnson & JohnsonXarelto | $1,031 | $78,871101 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 322 cardiovascular disease providers in Wisconsin.
Other cardiovascular disease in Appleton
- Kevin ChenAppleton$20K
- Ameer KabourAppleton$16K
- Abdulmohsin AhmadjeeAppleton$15K
- Agei EnohAppleton$9K
- Richard Santa CruzAppleton$9K
- Dong Bo YuAppleton$7K
- Jagdeep SabharwalAppleton$6K
- Subhashish AgarwalBrookfield$378K
- Lee BibloMilwaukee$280K
- David GrambowMilwaukee$267K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.